Paper35543795
Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
Papp H and 3 others. Geroscience, 2022. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19? Papers, record 35543795. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35543795
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 Drug Treatment | Major topic |
| Aged | |
| Amides | |
| Humans | |
| Pyrazines | |
| SARS-CoV-2 | |
| Treatment Outcome |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29524445 | Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. | Antiviral Res | 2018 | https://conductscience.org/library/papers/29524445 | PubMed |
| 2 | 15728892 | Mechanism of action of T-705 against influenza virus. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15728892 | PubMed |
| 3 | 32346491 | Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. | Engineering (Beijing) | 2020 | https://conductscience.org/library/papers/32346491 | PubMed |
| 4 | 34914868 | Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34914868 | PubMed |
| 5 | 26798032 | Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. | Clin Pharmacokinet | 2016 | https://conductscience.org/library/papers/26798032 | PubMed |
| 6 | 34726479 | An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. | Science | 2021 | https://conductscience.org/library/papers/34726479 | PubMed |
| 7 | 32536670 | Uric Acid Elevation by Favipiravir, an Antiviral Drug. | Tohoku J Exp Med | 2020 | https://conductscience.org/library/papers/32536670 | PubMed |
| 8 | 32377677 | COVID-19 in older people: a rapid clinical review. | Age Ageing | 2020 | https://conductscience.org/library/papers/32377677 | PubMed |
| 9 | 15095236 | Nucleoside analogues and mitochondrial toxicity. | Clin Infect Dis | 2004 | https://conductscience.org/library/papers/15095236 | PubMed |
| 10 | 24951535 | Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. | J Antimicrob Chemother | 2014 | https://conductscience.org/library/papers/24951535 | PubMed |
| 11 | 32943628 | Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. | Nat Commun | 2020 | https://conductscience.org/library/papers/32943628 | PubMed |
| 12 | 35740211 | Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35740211 | PubMed |
| 13 | 33212256 | Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/33212256 | PubMed |
| 14 | 16084170 | Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? | Am J Med | 2005 | https://conductscience.org/library/papers/16084170 | PubMed |
| 15 | 34040117 | The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. | Sci Rep | 2021 | https://conductscience.org/library/papers/34040117 | PubMed |
| 16 | 32097670 | Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. | Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32097670 | PubMed |
| 17 | 32020029 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. | Cell Res | 2020 | https://conductscience.org/library/papers/32020029 | PubMed |
| 18 | 34044777 | Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. | BMC Infect Dis | 2021 | https://conductscience.org/library/papers/34044777 | PubMed |
| 19 | 34476717 | Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary. | Geroscience | 2021 | https://conductscience.org/library/papers/34476717 | PubMed |
| 20 | 34539392 | Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34539392 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39592539 | Advancements in Antiviral Therapy: Favipiravir Sodium in Nasal Formulation. | AAPS PharmSciTech | 2024 | https://conductscience.org/library/papers/39592539 | PubMed |
| 36903575 | Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. | Molecules | 2023 | https://conductscience.org/library/papers/36903575 | PubMed |
| 36160358 | Perspective: repurposed drugs for COVID-19. | Arch Med Sci | 2022 | https://conductscience.org/library/papers/36160358 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35543795
GET https://conductscience.org/api/papers/v1/35543795/references?page=2